Myriad Genetics reported significantly weaker-than-expected Q2 2026 financial results, including an 11% revenue decline, an operating loss, and reduced full-year revenue guidance, leading to a sharp after-hours stock drop. This indicates a major negative shift in the company's financial outlook and investor sentiment.
Myriad Genetics experienced a substantial after-hours stock decline of 37.8% following its Q2 2026 earnings report. The company missed revenue expectations, reporting an 11% year-over-year decrease, posted an operating loss, and significantly lowered its full-year revenue guidance while suspending its adjusted EBITDA outlook. This news is a major negative catalyst for investors, signaling deteriorating financial performance and uncertainty about future profitability. The immediate impact is a sharp sell-off, and traders should be aware of potential continued volatility as the market digests this information. While the company highlighted growth in its Cancer Care Continuum business and new initiatives, these were overshadowed by the overall poor financial results and outlook.